WO2004022103A3 - Foxp1 et ses utilisations - Google Patents

Foxp1 et ses utilisations Download PDF

Info

Publication number
WO2004022103A3
WO2004022103A3 PCT/GB2003/003881 GB0303881W WO2004022103A3 WO 2004022103 A3 WO2004022103 A3 WO 2004022103A3 GB 0303881 W GB0303881 W GB 0303881W WO 2004022103 A3 WO2004022103 A3 WO 2004022103A3
Authority
WO
WIPO (PCT)
Prior art keywords
foxp1
conditions mediated
estrogen receptor
treating
receptor
Prior art date
Application number
PCT/GB2003/003881
Other languages
English (en)
Other versions
WO2004022103A2 (fr
Inventor
Alison Banham
Stephen Fox
Adrian Harris
Original Assignee
Isis Innovation
Alison Banham
Stephen Fox
Adrian Harris
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0220776A external-priority patent/GB0220776D0/en
Priority claimed from GB0229134A external-priority patent/GB0229134D0/en
Application filed by Isis Innovation, Alison Banham, Stephen Fox, Adrian Harris filed Critical Isis Innovation
Priority to AU2003263326A priority Critical patent/AU2003263326A1/en
Publication of WO2004022103A2 publication Critical patent/WO2004022103A2/fr
Publication of WO2004022103A3 publication Critical patent/WO2004022103A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention se rapporte à FOXP1 et en particulier à l'utilisation de FOXP1 dans le traitement ou l'identification de patients souffrant d'états pathologiques ayant pour origine des perturbations ou des modifications dans le niveau de l'expression ou l'activité de FOXP1. Plus particulièrement, l'invention concerne une méthode de traitement de maladies ou d'états pathologiques corégulés par FOXP1 d'un récepteur nucléaire, tel qu'un récepteur d'oestrogènes. Cette méthode consiste à administrer un inhibiteur ou un amplificateur de l'interaction de FOXP1 et ledit récepteur d'oestrogènes à un individu en ayant besoin. L'invention concerne également d'autres méthodes, compositions, trousses et analyses associées à FOXP1.
PCT/GB2003/003881 2002-09-06 2003-09-08 Foxp1 et ses utilisations WO2004022103A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003263326A AU2003263326A1 (en) 2002-09-06 2003-09-08 Foxp1 and uses thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0220776.9 2002-09-06
GB0220776A GB0220776D0 (en) 2002-09-06 2002-09-06 FOXP2 and uses thereof
GB0229134.2 2002-12-13
GB0229134A GB0229134D0 (en) 2002-12-13 2002-12-13 Foxp1 and uses thereof

Publications (2)

Publication Number Publication Date
WO2004022103A2 WO2004022103A2 (fr) 2004-03-18
WO2004022103A3 true WO2004022103A3 (fr) 2004-06-03

Family

ID=31980020

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2003/003881 WO2004022103A2 (fr) 2002-09-06 2003-09-08 Foxp1 et ses utilisations

Country Status (2)

Country Link
AU (1) AU2003263326A1 (fr)
WO (1) WO2004022103A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005095447A2 (fr) * 2004-03-29 2005-10-13 Isis Innovation Limited Nouvelles proteines foxp1
WO2013063019A1 (fr) 2011-10-28 2013-05-02 The Wistar Institute Of Anatomy And Biology Méthodes et compositions utilisées pour augmenter l'effet thérapeutique des lymphocytes t anti-tumoraux
US20150118257A1 (en) * 2012-04-20 2015-04-30 The Wistar Institute Of Anatomy And Biology Methods and Compositions for Manipulating the Immune System

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BANHAM ALISON H ET AL: "The FOXP1 winged helix transcription factor is a novel candidate tumor suppressor gene on chromosome 3p", CANCER RESEARCH, vol. 61, no. 24, 15 December 2001 (2001-12-15), pages 8820 - 8829, XP002264689, ISSN: 0008-5472 *
FOX STEPHEN B ET AL: "FOXP1 expression is correlated with estrogen receptor (ER) in primary human breast carcinomas and co-localizes with ER in the nuclei of MCF-7 breast cancer cells.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL, vol. 44, July 2003 (2003-07-01), 94th Annual Meeting of the American Association for Cancer Research;Washington, DC, USA; July 11-14, 2003, July 2003, pages 1264, XP001156579, ISSN: 0197-016X *
SHU WEIGUO ET AL: "Characterization of a new subfamily of winged-helix/forkhead (Fox) genes that are expressed in the lung and act as transcriptional repressors", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 276, no. 29, 20 July 2001 (2001-07-20), pages 27488 - 27497, XP002264690, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
WO2004022103A2 (fr) 2004-03-18
AU2003263326A1 (en) 2004-03-29

Similar Documents

Publication Publication Date Title
WO2005084654A3 (fr) Procedes et compositions pour le traitement ou la prevention de troubles psychiatriques avec des inhibiteurs de cox-2 seuls et en combinaison avec des antidepresseurs
WO2003057698A3 (fr) Composes spiroazacycliques utilises comme modulateurs du recepteur de monoamine
TW200630096A (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
DE60327999D1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
AU2003220299A1 (en) Azinylaminoazoles as inhibitors of protein kinases
ECSP045520A (es) Metodos de tratamiento con inhibidores de la ptec y agentes antihipertensivos
WO2005030188A3 (fr) Derives de phenyl-piperazine en tant que modulateurs des recepteurs muscariniques
WO2004043456A8 (fr) Inhibiteurs d'absorption du cholesterol pour le traitement de la demyelination
BRPI0407913A (pt) antagonistas receptores de ccr-3
MXPA05013226A (es) Carbamatos de piperidina sustituidos, para el uso como inhibidores de la lipasa sensible a hormonas.
UA107177C2 (uk) Імуногенна композиція цвс2 та спосіб приготування такої композиції
WO2004022103A3 (fr) Foxp1 et ses utilisations
WO2005076824A3 (fr) Methodes de traitement du syndrome du colon irritable
MXPA05011157A (es) Nuevo metodo para modular la actividad relacionada a los huesos.
WO2003087336A3 (fr) Expression genetique a regulation alpha du recepteur d'oestrogene, dosages et therapeutique associes
BR0308517A (pt) Combinação de um antagonista do receptor de aldosterona e de um agente sequestrante de ácido biliar
WO2007148308A3 (fr) Compositions et trousses comprenant de la mélatonine et un acide gras oméga 3
WO2006078776A3 (fr) Inhibiteurs et procedes de traitement de maladies cardio-vasculaires, et procede pour l'identification d'inhibiteurs
EP1597234A4 (fr) Nouveaux composes
WO2003065044A3 (fr) Agents diagnostiques et therapeutiques destines a des maladies associees a gpr72
WO2004038405A3 (fr) Diagnostics et therapeutiques pour maladies liees au recepteur 43 couple a la proteine g (gpr43)
WO2004028447A3 (fr) Nouvelles compositions et methodes destinees au traitement du psoriasis
WO2004009028A3 (fr) Methodes et composition permettant de traiter et de prevenir l'infection grippale et les symptomes associes
WO2004031398A3 (fr) Diagnostic genetique de depression
WO2003066077A3 (fr) Outil de diagnostic et therapeutique pour des maladies associees au recepteur de neuromedine u1 (nmu1)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP